Physician profile
Jonathan D Weimer
NPI 1528596343
$3,850.16
in general payments reported to CMS, 2019-2025
29 companies · $886 in 2025
The $886 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $732 · 2022: $700 · 2023: $716 · 2024: $816 · 2025: $886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,417.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $601.58 | 2021-2025 | Mounjaro, Jardiance, Trulicity |
| Astrazeneca Pharmaceuticals LP | $462.18 | 2021-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $396.80 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $376.54 | 2021-2025 | Jardiance |
| Abbvie INC. | $327.34 | 2021-2025 | |
| Glaxosmithkline, LLC. | $237.07 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $228.68 | 2021-2025 | |
| Astellas Pharma US INC | $129.68 | 2021-2025 | Veozah |
| Biohaven Pharmaceuticals, INC. | $122.11 | 2021 | |
| Esperion Therapeutics, INC. | $114.39 | 2021 | |
| Abbott Laboratories | $108.64 | 2022-2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $105.99 | 2021-2025 | |
| Exact Sciences Corporation | $91.28 | 2023-2025 | Cologuard Collection Kit |
| Shield Therapeutics INC | $83.84 | 2023-2025 | Accrufer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.21 | 2021-2024 | Xifaxan |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $48.11 | 2025 | Flucelvax, Fluad |
| Novartis Pharmaceuticals Corporation | $42.43 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $37.44 | 2023-2024 | Quviviq |
| Xeris Pharmaceuticals, INC. | $35.52 | 2023-2025 | Keveyis, Gvoke Hypopen |
| Viiv Healthcare Company | $34.79 | 2024 | Rukobia |
| Janssen Pharmaceuticals, INC | $27.78 | 2021 | |
| Dexcom, INC. | $26.61 | 2025 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $24.76 | 2021 | |
| Sanofi-Aventis U.S. LLC | $24.73 | 2025 | |
| Alnylam Pharmaceuticals INC. | $22.03 | 2024 | Onpattro |
| Medtronic, INC. | $21.31 | 2025 | Intellis Adaptivestim |
| Phathom Pharmaceuticals, INC. | $19.98 | 2024 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $19.40 | 2022 | |
| Ethicon US, LLC | $11.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Weimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.